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Abstract
Zebrafish are becoming increasingly popular as an organism in which to model human disease and to study the
effects of small molecules on complex physiological and pathological processes. Since larvae are no more than a few
millimetres in length, and can live in volumes as small as 100 microliters, they are particularly amenable to high-
throughput and high content compound screening in 96 well plate format. There is a growing literature providing
evidence that many compounds show similar pharmacological effects in zebrafish as they do in mammals, and in
particular humans. However, a major question regarding their utility for small molecule screening for neurological
conditions is whether a molecule will reach its target site within the central nervous system. Studies have shown that
Claudin-5 and ZO-1, tight-junction proteins which are essential for blood-brain barrier (BBB) integrity in mammals,
can be detected in some cerebral vessels in zebrafish from 3 days post-fertilisation (d.p.f.) onwards and this timing
coincides with the retention of dyes, immunoreactive tracers and fluorescent markers within some but not all cerebral
vessels. Whilst these findings demonstrate that features of a BBB are first present at 3 d.p.f., it is not clear how
quickly the zebrafish BBB matures or how closely the barrier resembles that of mammals. Here, we have combined
anatomical analysis by transmission electron microscopy, functional investigation using fluorescent markers and
compound uptake using liquid chromatography/tandem mass spectrometry to demonstrate that maturation of the
zebrafish BBB occurs between 3 d.p.f. and 10 d.p.f. and that this barrier shares both structural and functional
similarities with that of mammals.
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Introduction
In mammals, the blood-brain barrier (BBB) provides a
complex obstacle to the penetration of drugs into the central
nervous system (CNS). The first level of barrier is presented by
the tight junctions between endothelial cells of the vasculature.
These high resistance tight junctions, made up by proteins
such as claudin-5 and ZO-1, render brain capillary endothelia
tightly sealed, in contrast to “leaky” endothelial capillaries in the
periphery. Thus, there is no paracellular movement of fluid and
only minimal pinocytosis from capillaries into the CNS [1]. The
next level of barrier function is provided by capillary pericytes,
which wrap around the endothelial cells of the capillary walls.
Lastly, the outermost layer comprises astrocyte end feet which
surround the endothelium and pericytes. In addition to
providing a physical barrier, these three cell types express a
variety of enzymes, such as aminopeptidases,
carboxypeptidases, endopeptidases and cholinesterases,
which inactivate many drugs [2], and in some cases, may also
activate pro-drugs. In spite of these physical and enzymatic
barriers, certain molecules are able to freely diffuse across the
BBB, but are prevented from accumulating in the brain as they
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are actively effluxed by specific transporters, the most notable
of which is P-glycoprotein (Pgp) [1]. Conversely, inwardly
directed transporter systems, such as GLUT1/Slc2a1 (glucose
transport), Slc7a1 and Slc7a5 (amino acids), low-density
lipoprotein receptors (LRPs) and ion pumps, permit the entry of
a variety of molecules that would otherwise be unable to enter
the brain [1].
Zebrafish are popular as a vertebrate model with which to
perform compound screens [3,4] and increasingly used to
model human neurological disease processes, such as
epilepsy and neurodegeneration [5,6]. Therefore, it is important
to understand whether and when the zebrafish BBB forms and
compare its characteristics and function with that of mammals.
Adult zebrafish express the tight junction proteins ZO-1 and
claudin-5 in the endothelial vascular cells within the brain [7]. In
addition, size dependent exclusion of immuno-reactive
compounds occurs in the adult zebrafish brain. For example,
analysis of the distribution of enzymatically active compounds
injected into the heart demonstrated that HRP (44kDa) was
retained in cerebral vessels, whilst sulfo-NHS-Biotin
(0.443kDa) diffused into the brain, indicating a size dependent
exclusion mechanism [7]. Tight junctions play a major role in
size-dependent exclusion in mammals and loosening of the
size exclusion limit is observed in claudin-5 knockout mice [8].
Therefore, the presence of claudin-5 and ZO-1 in the adult
zebrafish brain could account for these observed effects.
These findings demonstrate that adult zebrafish possess a
BBB but it is not known when this barrier becomes functional
during zebrafish development.
Expression of claudin-5 and ZO-1 have been detected in
cerebral microvessels of larval zebrafish from as early as 2 and
3 days post-fertilisation (d.p.f.) respectively [7,9]. Furthermore,
several studies have used fluorescent dyes or transgenically-
encoded fluorescently-tagged plasma protein to demonstrate
size dependent exclusion occurs from around 3 d.p.f. [7,9–11].
However, size exclusion seems to occur only in certain
cerebral vessels at this age, while others are still “leaky”. In
mammals, the BBB gradually matures during development,
with permeability to small molecules decreasing with age (i.e.
substances excluded from the adult rat brain do permeate
embryonic brain capillaries) [12]. Similarly, the developing
mouse BBB shows decreasing compound permeability as it
matures [13].
In this study, we set out to investigate how size-dependent
exclusion matures during larval development, to determine the
degree of similarity in exclusion properties to those of
mammalian BBB and to study the cellular components
surrounding the vascular endothelium in the brain. We show
that zebrafish do indeed gradually develop a sophisticated BBB
with active transport systems. This allows for the design of
rational strategies for screening compounds for neurological
indications and interpretation of results, as well as potentially
providing a system to predict whether a novel compound might
penetrate the human brain.
Methods
Ethics statement
This work was licenced by the Home Office under the
Animals (Scientific Procedures) Act (Home Office licence
number PPL80/2074 for work performed at DanioLabs Ltd and
PPL 80/2322 for work performed at the University of
Cambridge). Protocols were approved by the local Animal
Welfare Ethical Review Committee (AWERC); namely,
DanioLabs AWERC and University of Cambridge AWERC.
Appropriate steps were taken to ameliorate suffering in all
work. Experiments were designed with the minimum number of
animals necessary to produce meaningful results.
Husbandry and experimental procedures
Embryos were collected from matings of adults of wildtype
(TL, AB and WIK strains) and Tg(fli1a:EGFP)y1 transgenic fish
[14] kept under standard conditions [15]. Embryos were reared
in embryo medium (5 mM NaCl, 0.17 mM KCl,0.33 mMCaCl2,
0.33 mM Mg2SO4, 10-5% Methylene Blue) and staged using
standard criteria [16]. All experiments were carried out in
accordance with the Animals (Scientific Procedures) Act, 1986.
Dye exclusion experiments
Stocks of 2% Evans blue (961 Da) and 10% sodium
fluorescein (376 Da) in 0.9% saline were prepared and stored
at 4 °C. Larvae were anaesthetised by immersion in 0.2 mg/ml
3-amino benzoic acid (MS222) prior to being immobilised and
positioned laterally in 3% methyl cellulose in embryo medium
such that the heart was accessible. Larvae and juveniles from
2 days post-fertilisation (d.p.f.) to 30 d.p.f. were injected with
0.5 to 2 nl (depending on age) of dye or saline control into the
pericardial region, using a standard zebrafish microinjection
apparatus [15]. Fish were transferred to fresh embryo medium
to recover from anaesthesia, then viewed using a fluorescence
dissecting microscope at 1 hour intervals to determine the time
of uptake of the dye into the circulation and the time at which
dye had permeated from the circulation into non-vascular body
tissue. Representative images of dye distribution in vivo were
taken on a Zeiss AxioZoom V16 microscope with Apotome.
Dye and saline injected larvae were anaesthetised at 4 or 6
hours after injection and fixed in 4% paraformaldehyde in PBS.
Ten larvae per age group and injection treatment were
embedded in Sakura Tissue-Tek OCT (Bayer, Newbury, UK)
and frozen parasagittal sections were cut at 10 µm thickness.
Quantification of dye fluorescence
Sections were visualised without mounting medium by
fluorescence microscopy on an Olympus BX51 microscope.
Three midline sagittal sections from each larva were identified
and images were captured using a ColorView camera
(Olympus) and AnalySis software (Soft Imaging System). The
fluorescence intensity within the brain was quantified for each
midline section of each larva in each treatment group using
colour threshold and area measurements in AnalySis. Mean
values, standard deviations and Student’s t-tests were
calculated using Excel software (Microsoft Office).
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Transmission Electron Microscopy
Larvae were anaesthetised at 3, 5, 8 and 10 d.p.f. by
immersion in 0.2 mg/ml MS222, fixed in 4% glutaraldehyde in
cacodylate buffer containing 0.006% hydrogen peroxide for 3
hours and washed in cacodylate buffer before post-fixing in
osmium tetroxide. Samples were bulk stained with uranyl
acetate, dehydrated in ethanol and embedded in Spurr’s resin.
Thin parasagittal sections (5 nm) were prepared with a Leica
Ultracut UCT, stained with uranyl acetate and lead citrate and
viewed in a Philips CM100 electron microscope at 80 KV.
In silico sequence analysis
Protein sequences of mammalian and zebrafish ABCB gene
family members were identified from ENSEMBL (human
GRCh37; mouse GRCm38; zebrafish Zv9). BLAST searches
were performed to identify whether un-annotated paralogues
could be identified from the zebrafish genome. Sequence
alignments were performed using ClustalW.
Zebrafish abcb1/4/5 expression
Larvae were anaesthetised at 3, 5, 8 and 10 d.p.f. by
immersion in 0.2 mg/ml MS222, fixed in 4% PFA and
processed for wholemount antibody staining as previously
described [17]. Immunohistochemistry was performed with an
antibody raised against mouse ABCB1 (Covance) at 1:100
dilution and the staining detected using Alexa568 fluorescent
secondary antibody (Molecular Probes). Larvae were mounted
in chamber slides in Prolong Gold antifade mounting medium
(Invitrogen) and viewed using a Zeiss StereoZoom V16
microscope under fluorescence illumination. Optical sectioning
was performed using an Apotome.2 (Zeiss) and representative
images were captured using and AxioCam MR digital camera
(Zeiss) and Zen 2012 software (Zeiss).
Drug exposure and distribution experiments
Initial drug exposure assays were performed in larval
zebrafish to identify a sufficiently high concentration of drug
that could be detected by liquid chromatography/tandem mass
spectrometry (LC/MS/MS) analysis without causing toxicity.
Maximum tolerated concentration (MTC) was determined using
n=6 larvae per group. A non-toxic drug concentration of 15
µg/ml was selected for all subsequent compound exposure
experiments except for scopolamine, which was used at 5
µg/ml. 60 larvae (equivalent to approximately 20 mg wet tissue)
were transferred into a single well of a 12 well plate (Corning)
and the final volume of embryo medium per well was adjusted
to 1.5 ml. Compounds of interest were prepared as 2 mg/ml
stocks in dimethyl sulfoxide (DMSO). 11.25 µl of stock was
added to each well, except for scopolamine (3.75 µl). Larvae
were incubated in the drug for 1 hour at room temperature then
anaesthetised on ice. For whole uptake analysis, anaesthetised
larvae were transferred to 1.5 ml microfuge tubes and all
excess liquid was removed. 100 µl ice cold PBS was added,
samples were briefly centrifuged and all excess liquid was
removed. For brain versus body uptake analysis, larvae were
anaesthetised by chilling prior to decapitation using fine
iridectomy scissors and No. 5 watchmaker forceps. Head and
body tissue samples were collected in separate microfuge
tubes on ice and excess liquid removed. 100 µl ice cold PBS
was added and samples were briefly centrifuged and all excess
liquid removed. The weight of the tissue sample was measured
and the samples were frozen at -20 °C prior to extraction for
LC/MS/MS.
For studies investigating the effect of Abcb1/4/5 efflux on
drug distribution, larvae were exposed to the ABCB1/4/5 efflux
inhibitor verapamil at 50 µg/ml, a concentration previously
demonstrated to be non-toxic, for 2 hours prior to exposure to
the test compound. Test compound was added to the well
containing 50 µg/ml verapamil and larvae were incubated for a
further hour at room temperature prior to tissue collection as
described. For subsequent LC/MS/MS analysis, tissue samples
were thawed and after addition of an internal standard
(clozapine) extracted into an organic solvent (tertiary-butyl
methyl ether, t-bme). The solvent extract was then evaporated
and reconstituted in methanol/acetic acid, except for
scopolamine exposed samples, which were reconstituted in
acetonitrile/ammonia. Liquid chromatography for haloperidol,
desloratadine and diphenhydramine (100 µl injections of
extracted samples) was carried out using a Phenomenex Luna
C18(2), 50 x 2 mm, 5 µm analytical column with a mobile
phase gradient given in Table S1. Chromatography for
scopolamine and scopolamine N-butyl bromide was performed
using a Restek Ultra IBD, 150 x 3.2 mm, 5 µm analytical
column with a mobile phase gradient given in Table S2. The
analytes and internal standard were ionised under atmospheric
pressure chemical ionisation (APCI) conditions operating in
positive ion mode. Detection was via tandem mass
spectrometry (MS/MS) using selected ion monitoring (SIM).
MS/MS scan parameters under APCI conditions are given in
Table S3. All analyses were performed using a Finnigan LCQ
quadrupole ion trap mass spectrometer. The ratio of the
amount of drug found in the trunk relative to that in the head
was calculated. Changes in trunk/head drug ratios of greater
than 20% were considered to be indicative of altered
distribution.
The effect of Pgp inhibitors on the distribution of
rhodamine 123
Rhodamine 123 (R123) was dissolved in 10% ethanol/0.9%
saline to make a 0.5 mg/ml stock. Dye exclusion experiments
on larvae at 3, 5, 8 and 10 d.p.f. were performed as described
above using 0.2 nl R123. Some larvae were exposed to
verapamil at 50 µg/ml for 2 hours prior to and during
intrapericardial injection of R123 and for 3 hours after injection.
At 3 hours after injection, larvae were anaesthetised and fixed
in 4% PFA prior to processing for frozen sections.
Quantification of fluorescence in the brain was performed as
described above.
Analysis of GFAP expression
Tg(fli1a:EGFP)y1 larvae at 3, 5, 7 and 10 d.p.f. were fixed in 4
% PFA, then processed for antibody staining as previously
described [17]. The GFAP antibody (zrf-1, ZIRC) was used at
1:25 dilution and detected with Alexa568 fluorescent secondary
antibody. Larvae were mounted in chamber slides in Prolong
Formation of the Zebrafish Blood-Brain Barrier
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e77548
Gold antifade mounting medium (Invitrogen) and viewed using
a Zeiss StereoZoom V16 microscope under fluorescence
illumination. Optical sectioning was performed using an
Apotome.2 (Zeiss) and representative images were captured
using and AxioCam MR digital camera (Zeiss) and Zen 2012
software (Zeiss).
Results
Developmental changes in the size of fluorescent
molecules excluded from the CNS
Dye exclusion experiments have long been used in rodent
investigations into the integrity of the BBB [1,18–21]. The
absence of dyes within the CNS following injection into
peripheral vessels can be used as a marker of BBB integrity.
We therefore used dyes of varying molecular weights to
determine the developmental timecourse of size dependent
exclusion from the zebrafish CNS. Dye exclusion experiments
were initially performed on larvae from 2 to 30 d.p.f. and after
initial analysis had narrowed down the relevant age range,
studies were limited to larvae at 3, 4, 5, 8 and 10 d.p.f. Larvae
were observed at 1 hour intervals after injection of the
fluorescent dye into the pericardial cavity to determine when
the fluorescent compound had diffused from the circulation into
peripheral tissues (Figure 1A & B). Larvae were then
anaethestised and fixed for cryosectioning. The fluorescent
intensity of frozen sections of brain tissue was quantified for
dye injected larvae and compared to saline injected siblings
fixed at the same time point after injection. An example of the
distribution and quantification process is shown in Figure 1C-E.
In Evans blue (961 Da) injected zebrafish, fluorescence was
observed in the brain at 3 d.p.f. but not at 5 d.p.f or subsequent
stages (Figure 1F), suggesting that molecules of high
molecular weight become excluded between 3 and 5 d.p.f. In
contrast, exclusion of sodium fluorescein, a lower molecular
weight compound (376 Da), was not observed until 10 d.p.f.
(Figure 1G), suggesting a time dependent maturation relating
to the size limit for molecules excluded from the CNS.
Expression of the zebrafish homologue of mammalian
P-glycoprotein is developmentally regulated
Previous studies have reported that zebrafish, like rodents,
have a duplicated abcb1 (P-glycoprotein, Pgp, or multi-drug
resistance) gene [22]. However, in the recent release of the
zebrafish genome sequence (Genome assembly: Zv9),
ENSDARG00000021787 is now annotated as abcb5 (reported
as abcb1a by [22]) and ENSDARG00000010936 as abcb4
(reported as abcb1b by [22]). In man, the ABCB gene family
comprises 11 members (ABCB1, 4, 5, 6, 7, 8, 9, 10, 11, TAP1
and TAP2) whereas in zebrafish, abcb1, abcb6 and tap2 are
missing, abcb11 is duplicated (abcb11a and abcb11b) and, in
addition, zebrafish possess abcb3l1. Phylogenetic analysis of
the mammalian and zebrafish abcb family suggests that the
zebrafish abcb5 (ENSDARG00000021787) and abcb4 genes
(ENSDARG00000010936) are the closest homologues of
mammalian ABCB1/4/5 (Figure 2) (see also Figure S1A and
S1B for alignment of human, mouse and zebrafish Abcb4 and
Abcb5 protein sequences). Peptide alignment analysis shows
that zebrafish Abcb4 has 63% similarity at the amino acid level
to human ABCB1 and 63% similarity to human ABCB4 (Table
1). The zebrafish abcb5 protein has 57% similarity at the amino
acid level to human ABCB1 and 50% to human ABCB5 (Table
1). BLAST searches of the latest zebrafish genome release
(Ensembl Zv9) with both human ABCB1 and mouse ABCB1A
and ABCB1B identify zebrafish Abcb4 and Abcb5 as the
closest zebrafish homologues to mammalian ABCB1.
Since no specific orthologue of mammalian ABCB1 could be
identified in the zebrafish genome (zv9), and since mammalian
ABCB4 and ABCB5 are known to be expressed in the vascular
endothelial cells of the CNS [1], we hypothesised that zebrafish
Abcb4 or Abcb5 might function as efflux transporters in the
vasculature surrounding the CNS and therefore investigated
the expression of these proteins.
Using an antibody against a highly conserved amino acid
sequence found in all mammalian Pgp isoforms [23] and also
present in zebrafish Abcb4 and Abcb5 (Figure 3A), optical
sections of wholemount Tg(fli1a:EGFP)y1 larvae at 10 d.p.f.
revealed specific staining in the vascular endothelium of the
CNS. A range of larval ages were then examined to determine
the earliest time point with specific vascular staining. Staining
was observed in the vascular endothelium of the CNS at 8
d.p.f. (Figure 3B & C) but not earlier (Figure S2). Based on
phylogenetic analysis, peptide homology and protein
expression, we assume that either the zebrafish abcb5
(ENSDARG00000021787) or abcb4 gene
(ENSDARG00000010936) is the functional homologue of
mammalian ABCB1 and is hereafter referred to as abcb1/4/5.
Expression of zebrafish Abcb1/4/5 correlates with the
onset of active transport across the blood brain barrier
Dye exclusion experiments were performed with Rhodamine
123 (R123), a fluorescent substrate for ABCB1 [24], ABCB4
[25] and ABCB5 [26] in mammals, to investigate the function of
Abcd1/4/5 during zebrafish development. R123 was excluded
from the brain at 8 d.p.f., but not at 3 and 5 d.p.f (Figure 4).
This time line coincides well with the expression of Abcb1/4/5
in the vascular endothelium of the CNS. To investigate whether
the exclusion of R123 was indeed due to efflux mediated by a
Abcb1/4/5 transporter, dye exclusion experiments were
repeated in the presence of verapamil, a known inhibitor of
mammalian ABCB1 [24], ABCB4 [25] and ABCB5 [27]. Larvae
were incubated in 50 µg/ml verapamil prior to, during and after
injection of R123 and analysed 3 hours after injection for
distribution of R123 fluorescence. In the presence of verapamil,
R123 penetrated into the brain also at 8 d.p.f. and 10 d.p.f.
(Figure 4). Since R123 was excluded from the brain at these
time points when incubated without verapamil, these results
suggests that R123 is actively transported out of the brain by
zebrafish Abcb1/4/5 from 8 d.p.f.
The formation of a blood brain barrier correlates with
developmental changes in drug distribution
A panel of 5 drugs known to either cross or not cross the
BBB in mammals were selected to test in zebrafish larvae.
Larvae of different ages were exposed to these compounds at
non-toxic concentrations for 1 hour prior to collection of head
Formation of the Zebrafish Blood-Brain Barrier
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and trunk tissue for analysis of drug concentration. A generic
extraction method was developed and LC/MS/MS was
performed to analyse the concentration of drug in head and
trunk tissue in larvae of different ages. Drug/tissue
concentrations were normalised against a standard and the
relative amount of drug in head and trunk samples was
compared to determine whether the drug distribution altered
with larval age (Table 2). The amount of drug absorbed over
the 1 hour exposure period varied greatly with some larval
tissue containing as little as 5.9 % of the medium concentration
for scopolamine N-butyl bromide and as much as 949% of the
medium concentration for haloperidol, a variation that may
reflect the hydrophobic/hydrophilic properties of the drugs
tested. Indeed, there is a loose correlation between the
partition coefficient (logP) value for each compound and the
percentage of the drug absorbed from the medium. In addition,
the absorption of each drug was found to vary between the
different larval ages examined. This may reflect the maturation
of different absorption routes, such as gut and gills and/or
onset of expression of metabolising enzymes.
All drugs were equally distributed in head and trunk samples
at 5 d.p.f., indicating the absence of a BBB at this age.
Furthermore, diphenhydramine and haloperidol, which do cross
the BBB in mammals, showed an equal distribution in head and
trunk samples at all ages examined, indicating that these drugs
also cross the zebrafish BBB. In scopolamine treated larvae,
the drug level was below the detection limits at 5 and 8 d.p.f.
However, scopolamine was detected at equal concentrations in
head and trunk samples in 10 d.p.f. larvae, suggesting that
scopolamine also crossed the BBB, as in mammals. In
contrast, scopolamine N-butyl bromide and desloratadine, two
drugs that do not cross the mammalian BBB, showed lower
concentrations in the head versus the trunk at 10 d.p.f. and
from 8 d.p.f. respectively, suggesting that these compounds
are also excluded from the brain in zebrafish larvae. Exclusion
of desloratadine at 8 d.p.f. correlates with the earliest
expression of Abcb1/4/5 in the vascular endothelium. Since it is
Figure 1.  Investigation of blood-brain barrier maturation using fluorescent dyes.  Ai-iv) One hour after pericardial injection of
Evans blue into 8 d.p.f. Tg(fli1a:EGFP)y1 larvae, strong Evan’s blue fluorescence could be observed in the dorsal aorta (arrows) and
vena cava (arrowheads) and weak fluorescence could be observed in individual segmental vessels of the trunk. Bi-iv) 4 hours after
injection of Evan’s blue, strong fluorescence is still observed in dorsal aorta and vena cava and additionally in segmental vessels. In
addition, fluorescence is also observed in trunk muscles between the segmental vessels and in the fin mesenchyme demonstrating
that the dye has penetrated into surrounding tissue. Ci) Parasagittal section of a 3 d.p.f. zebrafish larva 3 hours after pericardial
injection with saline control. Cii) High magnification fluorescent imaging of the region of marked in Ci). Di) Parasagittal section of a 3
d.p.f. zebrafish larva 3 hours after pericardial injection with Evan’s blue. Dii) High magnification fluorescent imaging of the region of
marked in Di). Ei) Parasagittal section of a 5 d.p.f. zebrafish larva 3 hours after pericardial injection with Evan’s Blue. Cii) High
magnification fluorescent imaging of the region of marked in Ci). Cii – Eii) The fluorescent intensity of dye within the brain was
quantified using image thesholding (pseudo-coloured green) and area over threshold was measured using AnalySis software. F &
G) The fluorescence intensity of injected dyes was measured in the brain of zebrafish following peripheral injection at various time
points of zebrafish development. Graphs show mean fluorescent intensity (± std dev.) for each treatment. F) Evans blue, (961 Da) a
large molecule known to form multimers with serum proteins, is excluded from the brain from day 5. G) Sodium fluorescein (376 Da)
permeates into the brain until 8 d.p.f. but is excluded at 10 d.p.f. Scale bar represents 250 µm in A and B and 50 µm in C - E.
doi: 10.1371/journal.pone.0077548.g001
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known that this drug is actively exported by Pgp (ABCB1) in
mammals, we investigated whether the distribution of this drug
would be altered by co-incubation with the ABCB1, ABCB4 and
ABCB5 inhibitor, verapamil. Co-incubation with verapamil
resulted in equalisation of the distribution of desloratadine in
head and trunk samples at 8 d.p.f and an accumulation in the
head versus the body at 10 d.p.f. Therefore, the exclusion of
desloratadine from 8 d.p.f is dependent on the function of
Abcb1/4/5 in zebrafish.
Figure 2.  Phylogenetic analysis of mammalian and
zebrafish ABCB genes.  Phylogenetic analysis of the ABCB
gene family in human, mouse and zebrafish. The zebrafish
genome does not contain an annotated orthologue of
mammalian ABCB1. Zebrafish abcb4 and abcb5 are identified
as the closest homologues to mammalian ABCB1, 4 and 5.
doi: 10.1371/journal.pone.0077548.g002
Table 1. Similarity between human, mouse and zebrafish
ABCB1, ABCB4 and ABCB5 peptide sequences.
 Zebrafish Abcb4 Zebrafish Abcb5
Human ABCB1 63% 57%
Human ABCB4 63% 55%
Human ABCB5 54% 50%
Mouse ABCB1A 63% 56%
Mouse ABCB1B 61% 56%
Mouse ABCB4 63% 54%
Mouse ABCB5 52% 48%
Peptide sequences were aligned using ClustalW.
doi: 10.1371/journal.pone.0077548.t001
Anatomical features of a blood brain barrier
Having established that exclusion of small molecules from
the zebrafish brain occurs between 3 and 10 d.p.f. (depending
on the size of the molecule and the method of exclusion), we
undertook an anatomical timecourse analysis using
transmission electron microscopy (TEM) to determine whether
there was also anatomical evidence for a BBB and if so, to
characterise the maturation of these features. At 3 d.p.f., no
evidence of tight junctions in the vessels around the brain and
spinal cord was observed (Figure 5A & B). At 5 d.p.f., however,
tight junctions were identified in some, but not all vascular
endothelium (data not shown). By 10 d.p.f., double membranes
were observed in the vascular endothelium at all sites
investigated, suggesting that tight junctions are present by this
age (Figure 5C & D). In addition, pericytes and astrocyte feet
processes were observed in some sections at 10 d.p.f. (Figure
5E) and evidence for the latter was further supported by the co-
localisation of glial fibrillary associated protein (GFAP) with
GFP-positive vessels in the brains of Tg(fli1a:EGFP)y1 larvae at
10 d.p.f. but not earlier (Figure S3).
Discussion
The zebrafish BBB matures during larval development
Several studies have demonstrated that dyes or
enzymatically active compounds are retained within cerebral
microvessels of the larval zebrafish brain from as early as 3
d.p.f. [7,9–11], co-incident with the expression of the tight
junction proteins ZO-1 and claudin5. However, these studies
showed exclusion from only some, but not all cerebral vessels
suggesting that there is not a fully functional BBB at this point.
Here, we have combined anatomical analysis by TEM,
functional investigation using fluorescent markers and
compound uptake using LC/MS/MS to investigate the formation
of the functional BBB in zebrafish and to demonstrate how this
barrier matures during larval development. By administrating
dyes of different molecular weights, we have shown that large
molecular weight compounds are indeed excluded at 3 d.p.f.
Although Evans blue is a fairly small molecule (961 Da), most
of the dye becomes bound to serum albumin and has a size of
>69kDa, therefore exclusion at 3 d.p.f. likely demonstrates
exclusion of serum proteins and this is in keeping with the size
exclusion findings from other studies [7,9–11]. By contrast,
exclusion of sodium fluorescein (molecular weight of 376Da)
does not take place until 10 d.p.f. indicating that the size
dependent exclusion of molecules from the brain matures
during larval development.
The zebrafish BBB possesses active transport systems
Active transport systems play a critical role in the function of
the BBB in mammals. The most significant transporter in
mammals is ABCB1 protein (Pgp), although other ABCB family
transporters and organic anion transporters are also expressed
by brain endothelial cells (reviewed in 1). These transporters
have diverse but overlapping substrate specificities that help
determine the partitioning of small molecules between the
blood and the brain. A clinical example of the role of Pgp efflux
is the non-sedating effects of second-generation
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antihistamines. Unlike the first generation counterparts (e.g.
hydroxyzine, diphenhydramine and triprolidine), loratadine,
desloratadine (the active metabolite of loratadine), and
cetirizine (the active metabolite of hydroxyzine) are actively
effluxed from the brain by Pgp and therefore do not have a
sedative effect [28].
In mammals, ABCB1 is present in epithelial cells specialised
in the secretion and excretion of undesired molecules,
particularly in the gut, liver, kidney and BBB. Several different
variants of ABCB5 are expressed in different tissues in
humans; ABCB5.ts encodes the longest protein (1257 aa),
believed to be a full transporter (i.e. the single protein functions
Figure 3.  Sequence comparison and expression of zebrafish ABCB1/4/5 homologues.  A) Sequence alignment of human
and mouse ABCB1 protein sequences with zebrafish Abcb4 and Abcb5. The zebrafish proteins show a high level of
identity with the mouse and human ABCB1, ABCB4 and ABCB5 proteins. An antibody recognising the peptide sequences
VQAALD (yellow) and VQEALD (blue) (Covance) was selected for use in zebrafish as the similarity of these peptides was
conserved. B (low magnification) and C) (high magnification) 3D projections of optically sectioned wholemount
Tg(fli1a:EGFP)y1 larvae stained with the anti-VQAALD antibody. Positive staining is observed in the vascular endothelium
of the CNS at 8 d.p.f , but not at earlier timepoints (see Figure S2). High magnification images (Ci-iii) demonstrate the co-
localisation of ABCB1/4/5 antibody staining (red) on cerebral vessels (green). Bi and Ci – GFP channel – maximum
intensity projection of the cerebral vasculature of Tg(fli1a:EGFP)y1 transgenic larvae; Bii and Cii – Alexa 568 labelled
antibody staining with ABCB1/4/5 antibody; Biii and Ciii – overlay.
doi: 10.1371/journal.pone.0077548.g003
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as an efflux pump) with expression restricted to the testis;
ABCB5 beta (812 aa) encodes a half-transporter which is only
active as a dimer and expression is restricted to pigment cells.
Evolutionary analysis of ABCB5 has shown that the ancestral
gene is a full transporter and that ABCB5, 1, 4 and 11 share a
common ancestor which began duplicating early in the
evolution of the chordate lineage. Zebrafish have homologues
of ABCB4 and ABCB5, but not ABCB1. The expression of
zebrafish Abcb1/4/5 in the vasculature suggests that these
proteins may fulfil the role of mammalian Pgp. By
immunohistochemical and dye exclusion experiments, we have
shown here both anatomical and functional evidence for active
transport of molecules across the BBB in zebrafish. Abcb1/4/5
is first detected in the vascular endothelium of the CNS at 8
d.p.f. Thus whilst non-Pgp/ABCB5 substrate small molecules
(e.g. sodium fluorescein) can penetrate the BBB and remain in
Figure 4.  Rhodamine 123 distribution is altered in the presence of verapamil.  A) Dye distribution and quantification
experiments using rhodamine 123 (R123) were performed as described for Figure 1. Graph shows mean fluorescent intensity (± std
dev.) for each treatment. Rhodamine 123 (grey bars), a substrate for mammalian ABCB1, ABCB4 and ABCB5, was excluded from
the brain by 8 d.p.f. which, coincides with the onset of zebrafish Abcb/4/5 staining in the vasculature of the CNS. When 8 d.p.f. and
10 d.p.f. larvae were incubated with verapamil (white bars), an inhibitor of ABCB1, ABCB4 and ABCB5 in mammals, R123 failed to
be excluded, consistent with blocked Abcb1/4/5 function. B and C) Representative images of parasagittal section of 5 d.p.f. larvae
following pericardial injection of saline (B) or Rhodamine 123 (C). Fluorescence in the brain is observed following injection of
Rhodamine 123. Scale bar represents 50 µm.
doi: 10.1371/journal.pone.0077548.g004
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the brain until day 10, Pgp/ABCB1/4/5 substrates (e.g. R123
and desloratidine) are actively effluxed from day 8.
A zebrafish model for BBB compound penetration
The presence of the BBB has been one of the greatest
obstacles in the development of drugs to treat neurological
conditions, with less than 1% of small molecules penetrating
this barrier. Various models have been developed to predict
drug permeation through membranes. For example,
measurements of drug partitioning in solvents is widely
employed, although perfusion through solvents is not identical
to diffusion across biological membranes and provides no
information about active transport systems [29]. Indeed, as a
result of transport proteins such as P-glycoproteins, the net
distribution in the CNS of a variety of hydrophobic drugs, such
as digoxin, cyclosporin and loperamide, is relatively low [30].
Models of BBB involving cell culture systems play some role in
assessing whether drugs may cross the BBB, but are limited in
that transport systems and blood-brain barrier enzymes may be
severely down regulated or not present at all [31]. Furthermore,
cells in such culture systems do not form rigid tight junctions.
Here, we have demonstrated that zebrafish larva may be
used as an in vivo tool for the prediction of compound
distribution. In accordance with other studies on compound
uptake in larval zebrafish [32,33], we observed a loose
correlation between the amount of compound absorbed and its
logP value. The compound with the highest logP, haloperidol,
showed highest accumulation in larvae and the compounds
with low logP (scopolamine and n-butyl scopolamine) showed
least absorption. However, 2 compounds with logP of
approximately 3.2 (diphenhydramine and desloratidine) did not
show a consistent pattern in the percentage of compound
absorbed. This suggests that hydrophobic properties of a
compound are not the sole determinant of their uptake into
zebrafish and is in keeping with findings of previous studies
[33]. Nevertheless, our study confirmed that all 5 compounds
tested showed the same distribution in older zebrafish larvae
as in mammals. An equal ratio of trunk/head drug distribution
(i.e. trunk/head= 1.0) was observed at all ages for
scopolamine, diphenhyramine and haloperidol, compounds
known to cross the BBB in mammals. By contrast, ratios of
greater than 1.2 were observed for scopolamine N-butyl
bromide (at 10 d.p.f.) and desloratidine (at 8 and 10 d.p.f.),
compounds that do not cross the mammalian BBB. In
mammals, drug distribution is calculated as brain:plasma
ratios. These studies show higher exclusion ratios than
observed in zebrafish e.g. 1:8 for desloratadine and 1:20 for
fexofenadine [34]. While this may suggest that the BBB may
not yet be fully formed in larval zebrafish, our findings with dye
exclusion assays would suggest otherwise. It is more likely that
the lack of a more dramatic exclusion ratio is due to the
exposure route (i.e. via immersion), or collection and analysis
of whole head rather than brain tissue in the current study (in
contrast to analysis on isolated brain and plasma samples in
mammals). A more definitive analysis of compound distribution
Table 2. Age-dependent changes in distribution of drugs in zebrafish larvae.
Drug (BBB penetration in mammals)LogP1 Age (d.p.f.)
Absorption (whole body) (%
uptake) Head concentration (µg/g)Trunk concentration (µg/g)Trunk/Head ratio
Scopolamine 0.98 5 - - - -
(penetrant)  8 - - - -
  10 12.8 .65 .63 1
Scopolamine N-butyl bromide -1.11 5 7.2 .89 1.26 1.4
(excluded)  8 5.9 .88 .87 1
  10 11.3 1.47 1.93 1.3
Diphenhydramine 3.27 5 142.4 21.63 21.08 1
(penetrant)  8 184.1 31.21 24.03 0.8
  10 358.7 52.8 54.8 1
Haloperidol 4.3 5 732.6 115.5 104.29 0.9
(penetrant)  8 949.5 136.35 148.51 1.09
  10 713.5 112.7 101.35 0.9
Desloratadine (excluded) 3.2 (XlogP) 5 14.8 2.31 2.14 0.9
  8 39.1 2.57 3.29 1.3
  10 28.5 3.38 5.17 1.5
Desloratadine + verapamil  5 18.4 2.89 2.64 0.9
  8 7.9 1.17 1.2 1
  10 48.9 8.57 6.12 0.7
1 LogP values were obtained from ChemIDplus (http://chem.sis.nlm.nih.gov/chemidplus/); where LogP values were not available, XLogP values were obtained from
PubChem (http://pubchem.ncbi.nlm.nih.gov/). Zebrafish larvae were exposed to 15 µg/ml of the test compound (5 µg/ml for scopolamine) for 1 hour and then collected for
LC/MS/MS analysis. Absorption in whole larvae was calculated as percentage of drug concentration in the tissue compared to the medium. Drug concentrations from head
and trunk tissue were calculated from duplicate samples and trunk/head ratio was used to highlight unequal tissue distribution as an indicator of BBB effects. Differences of
greater than 20% (i.e. trunk/head ratio > 1.2) were considered to indicate lack of BBB penetration.
doi: 10.1371/journal.pone.0077548.t002
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Figure 5.  Transmission electron microscopy analysis of blood-brain barrier maturation.  Parasaggital sections through the
brain of zebrafish larvae at 3 d.p.f. and 10 d.p.f. A) At 3 d.p.f., blood vessels (bv) surrounding the brain are simple in structure. B) At
high resolution, only a single membrane is observed (arrows) no evidence of double membranes was observed at any location
examined. C) At 10 d.p.f., blood vessels surrounding the CNS are more complex in structure. D) At high resolution, a double layer
membrane is apparent (arrows), indicative of the presence of tight junctions. E) In some vessels at 10 d.p.f., pericytes (pc) could be
observed surrounding endothelial cells (ec). In addition, astrocyte endfeet (ae) were observed around some vessels at 10 d.p.f. but
not at earlier ages. Magnification: A & C 5.2K; B, D & E 15.5K.
doi: 10.1371/journal.pone.0077548.g005
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before and after BBB formation might be achieved by injection
of compounds directly into the circulation. However, in our
study, we sought to replicate the conditions used in standard
zebrafish chemical screens, i.e. compound exposure by
immersion, in order to determine whether the formation of the
BBB limits the penetration of certain compounds into CNS
tissue. These findings will therefore be of more relevance to
groups performing compound screens with neurological and
neurobehavioural endpoints and suggest that even following
immersion (where absorption is thought to occur through the
skin, gut and gills), compounds may be (partially) excluded
from the CNS in older larvae. Since the 5 d.p.f. zebrafish larva
is only 2-3 mm in length, brain dissection was not possible, and
head samples therefore also contained non-CNS tissue such
as skin, bone, muscle and gills. Nevertheless, our results
suggest that changes from the 1:1 head:trunk concentration
ratio can be used as an indicator of exclusion from the brain.
These data would therefore suggest that zebrafish may be
useful in determining whether a compound would penetrate the
BBB in vivo, but not for accurate quantification. For example,
analysis of compound uptake in head versus trunk at 5 d.p.f.
and 10 d.p.f. could be used as a method for predicting BBB
penetration. In addition, analysis of drug distribution at different
larval ages (i.e. before and after the onset of Abcb1/4/5
expression) allows analysis of whether a particular drug is
actively effluxed. Since the use of zebrafish screens to identify
novel therapeutics is gaining popularity [35,36], these results
allow for the rational screening of small molecules for CNS
endpoints in zebrafish by appropriate age selection.
In summary, the demonstration of a BBB in zebrafish larvae
lends further weight to their importance as an experimental
species for drug discovery, particularly for neurological
indications. Furthermore, since the barrier is formed in larvae
by 10 d.p.f., zebrafish may provide a rapid and accurate in vivo
model for the prediction of BBB permeability for novel
compounds.
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Figure S1.  Alignment of human, mouse and zebrafish
ABCB4 and ABCB5 protein sequences. A) Alignment of
human, mouse and zebrafish ABCB4 protein sequences. B)
Alignment of human, mouse and zebrafish ABCB5 protein
sequences. Peptide sequences were aligned using ClustalW.
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Figure S2.  Expression of zebrafish ABCB1/4/5 homologue
at 3 d.p.f. Maximum intensity projection of the cerebral
vasculature of Tg(fli1a:EGFP)y1 transgenic embryos at 3 d.p.f.
A) GFP labels the vasculature; B) Alexa 568 labelled antibody
staining with ABCB1/4/5 antibody; C) overlay. ABCB1/4/5
antibody does not co-localise with the vascular endothelium at
3 d.p.f. although positive antibody staining is observed in the
liver primordium (arrowhead).
(TIF)
Figure S3.  Expression of GFAP around cerebral vessels.
Maximum intensity projections of Tg(fli1a:EGFP)y1 transgenic
larvae stained with GFAP antibody. A) At 7 d.p.f., GFAP
staining is observed in the glia but does not co-localise with
GFAP in the vasculature. B (low magnification) and C (high
magnification) At 10 d.p.f., GFAP staining is observed in some
cerebral vessels (arrowheads). Scale bar represents 50 µm.
(TIF)
Table S1.  LC conditions for haloperidol, desloratadine and
diphenhydramine.
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Table S2.  LC conditions for scopolamine and scopolamine
N-butyl bromide.
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